Takeda Updates HEMOFIL® M and RECOMBINATE Availability for Hemophilia A Patients

Takeda Updates HEMOFIL® M and RECOMBINATE Availability for Hemophilia A Patients

The National Bleeding Disorders Foundation (NBDF) is alerting the community to updated information from Takeda Pharmaceutical Company regarding the discontinuation timelines for HEMOFIL® M and RECOMBINATE®, two therapies used to treat hemophilia A,